(Q37489472)

English

Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program

scientific article published on 19 May 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program (English)

1 reference

Europe PubMed Central

20 August 2017

0 references

0 references

arterial hypertension

0 references

liver cirrhosis

0 references

0 references

portal hypertension

1 reference

based on heuristic

inferred from title

author name string

Guadalupe Garcia-Tsao

1

1 reference

Europe PubMed Central

20 August 2017

Joseph K Lim

2

1 reference

Europe PubMed Central

20 August 2017

Members of Veterans Affairs Hepatitis C Resource Center Program

3

1 reference

Europe PubMed Central

20 August 2017

language of work or name

0 references

publication date

19 May 2009

1 reference

Europe PubMed Central

20 August 2017

The American Journal of Gastroenterology

1 reference

Europe PubMed Central

20 August 2017

104

1 reference

Europe PubMed Central

20 August 2017

7

1 reference

Europe PubMed Central

20 August 2017

1802-1829

1 reference

Europe PubMed Central

20 August 2017

Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Pharmacological treatment of portal hypertension: an evidence-based approach

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Meta-analysis: endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleeding

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Endoscopic band ligation in the treatment of portal hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Banding ligation versus beta-blockers as primary prophylaxis in esophageal varices: systematic review of randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

A pilot project examining the predicted preferences of patients and physicians in the primary prophylaxis of variceal hemorrhage

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Propranolol for the prevention of first esophageal variceal hemorrhage: a lifetime commitment?

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

A randomized study comparing ligation with propranolol for primary prophylaxis of variceal bleeding in candidates for liver transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: A preliminary study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Acetaminophen hepatotoxicity in alcoholics. A therapeutic misadventure

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Drug administration in chronic liver disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Definitions, methodology and therapeutic strategies in portal hypertension. A Consensus Development Workshop, Baveno, Lake Maggiore, Italy, April 5 and 6, 1990

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Effects of blood volume restitution following a portal hypertensive-related bleeding in anesthetized cirrhotic rats

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

A randomized controlled trial comparing ligation and sclerotherapy as emergency endoscopic treatment added to somatostatin in acute variceal bleeding

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Emergency transjugular intrahepatic portasystemic stent shunting as salvage treatment for uncontrolled variceal bleeding

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

The use of self-expanding metal stents to treat acute esophageal variceal bleeding.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

A randomized controlled trial of cyanoacrylate versus alcohol injection in patients with isolated fundic varices

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

A pilot study of 2-octyl cyanoacrylate injection for treatment of gastric fundal varices in humans

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Meta-analysis: Combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Prevention of variceal rebleeding

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

"A La Carte" treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

TIPS for prevention of recurrent bleeding in patients with cirrhosis: meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Endoscopic treatments for portal hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Portal hypertension and gastrointestinal bleeding.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Combined ligation and sclerotherapy versus ligation alone for secondary prophylaxis of esophageal variceal bleeding: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Spontaneous bacterial peritonitis: a historical perspective

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Prevention and treatment of infections in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Randomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous bacterial peritonitis in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Failure of current antibiotic first-line regimens and mortality in hospitalized patients with spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Association of interleukin-17F 7488 single nucleotide polymorphism and inflammatory bowel disease in the Chinese population

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Restricted use of albumin for spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Polymorphonuclear cell count response and duration of antibiotic therapy in spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Effects of oral ciprofloxacin on aerobic gram-negative fecal flora in patients with cirrhosis: results of short- and long-term administration, with daily and weekly dosages

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Effect of celecoxib on renal function in cirrhotic patients with ascites. A pilot study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Diuresis in the ascitic patient: a randomized controlled trial of three regimens

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Repeated paracentesis and i.v. albumin infusion to treat 'tense' ascites in cirrhotic patients. A safe alternative therapy.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Sustained aquaretic effect of the V2-AVP receptor antagonist, RWJ-351647, in cirrhotic rats with ascites and water retention.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Hyponatremia in cirrhosis: Results of a patient population survey.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Hyponatremia and mortality among patients on the liver-transplant waiting list

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

The transjugular intrahepatic portosystemic shunt for the management of cirrhotic refractory ascites

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Peritoneovenous shunt as a bridge to liver transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Outcome analysis of cirrhotic patients undergoing chest tube placement.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Tenofovir disoproxil fumarate: role in hepatitis B treatment

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Acute kidney injury in cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Pathogenesis and treatment of hepatorenal syndrome

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Diagnosis and treatment of acute renal failure in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Model for end-stage liver disease (MELD) and allocation of donor livers

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

The treatment of hepatic encephalopathy

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Normal protein diet for episodic hepatic encephalopathy: results of a randomized study.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Protein restriction in hepatic encephalopathy: necessary evil or illogical dogma?

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

ESPEN Guidelines on Enteral Nutrition: Liver disease.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Dietary and nutritional indications in hepatic encephalopathy

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Fine-needle aspiration biopsy of hepatic lesions: computerized tomographic-guided versus endoscopic ultrasound-guided FNA.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Prognosis of hepatocellular carcinoma: the BCLC staging classification

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Compensated cirrhosis: Natural history and prognostic factors

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Identifiers

10.1038/AJG.2009.191

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37489472&oldid=2148735762"